Nascent Biotech INC

Nascient Biotech announces the resignation of an independent director due to health reasons and reports a delinquency from the OTC for late filings.

Nascent Biotech has completed Phase 1 clinical trials for its cancer treatment Pritumumab and is preparing to begin Phase 2 trials, while reporting a net loss of $377,390 for the quarter ending June 30, 2024.

Nascent Biotech reports its financial results for the quarter ended December 31, 2023, highlighting progress in its Phase 2 clinical trials for brain cancer and ongoing financial challenges.

Nascent Biotech, a clinical-stage biopharmaceutical company, reported its full-year 2024 results, highlighting progress in its Pritumumab clinical trials and financial position.

Douglas John Karas, a director of Nascent Biotech Inc., acquired 50,000 shares of common stock at $0.10 per share on June 30, 2024, as part of his employment contract.

Lowell Thomas Holden, CFO of Nascent Biotech Inc., acquired 96,000 shares of common stock at $0.09 per share on June 30, 2024, as part of his employment contract.

Nascent Biotech's CEO, Sean Carrick, acquired 192,000 shares of common stock on June 30, 2024, as part of his employment contract.

Lowell Thomas Holden, CFO of Nascent Biotech Inc., reports the acquisition of 112,500 shares of common stock on March 31, 2024, as part of his employment contract.

Nascent Biotech's President and CEO, Sean Carrick, acquired 225,000 shares of common stock at a price of $0.1845 per share on March 31, 2024, as part of his employment contract.

Director Douglas Karas acquired 27,100 shares of Nascent Biotech Inc. (NBIO) at a price of $0.1845 on March 31, 2024, as part of his employment contract.

Nascent Biotech aims to raise capital for Phase 2 clinical trials and administrative expenses through a self-underwritten public offering of 20,000,000 shares of common stock at $0.15 per share.

Nascent Biotech aims to raise capital for Phase 2 clinical trials and administrative expenses through a stock offering involving the sale and resale of common stock and warrants.

Nascent Biotech is seeking to raise capital through a share offering to fund Phase 2 clinical trials for its cancer drug, Pritumumab, and cover general administrative expenses.